FULC - Company ID 0001680581
The table below shows Fulcrum Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $80.00M | $2.81M | $6.34M | $19.16M | $8.82M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $56.10M | $63.39M | $71.80M | $76.78M | $69.70M | $59.04M |
| SG&A |
Fulcrum Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $80.00M in fiscal 2024. Over the 6 fiscal years shown, annual revenue declined from $8.82M (FY 2020) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $28.67M |
| $36.45M |
| $41.67M |
| $41.69M |
| $30.52M |
| $21.39M |
| Operating income | -$84.77M | -$21.90M | -$110.66M | -$112.56M | -$81.05M | -$71.61M |
| Income tax | $0.00 | $0.00 | - | - | - | - |
| Net income | -$74.88M | -$9.73M | -$97.34M | -$109.87M | -$80.85M | -$70.82M |
| EPS (diluted) | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | -$2.79 |